Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing

Pharmaceutical Research

Volumn 25, Issue 1, 2008, Pages 167-175

  Overhoff, Kirk A ^a   McConville, Jason T ^a   Yang, Wei ^a   Johnston, Keith P ^b   Peters, Jay I ^c   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b The University of Texas at Austin   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Amorphous; In vitro in vivo correlation; Nanoparticle; Particle engineering; Rapid freezing; Supersaturation; Tacrolimus

Indexed keywords

DODECYL SULFATE SODIUM; NANOMATERIAL; POLOXAMER; POLYMER; POLYVINYL ALCOHOL; STABILIZING AGENT; TACROLIMUS;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG ABSORPTION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; FREEZING; MALE; NONHUMAN; PH; PRIORITY JOURNAL; RAT;

ACIDS; ANIMALS; AREA UNDER CURVE; DRUG COMPOUNDING; EXCIPIENTS; FREEZING; HYDROGEN-ION CONCENTRATION; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; MALE; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POLOXAMER; POLYVINYL ALCOHOL; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM DODECYL SULFATE; SOLUBILITY; TACROLIMUS; X-RAY DIFFRACTION;

EID: 38049112810     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9417-y     Document Type: Article

References (49)

1. D. H. Peters, A. Fitton, G. L. Plosker, and D. Faulds. Tacrolimus-a review of its pharmacology, and therapeutic potential in hepatic and renal-transplantation. Drugs 46:746-794 (1993).
2. W. J. Jusko, W. Piekoszewski, G. B. Klintmalm, M. S. Shaefer, M. F. Hebert, A. A. Piergies, C. C. Lee, P. Schechter, and Q. A. Mekki. Pharmacokinetics of tacrolimus in liver-transplant patients. Clin. Pharmacol. Ther. 57:281-290 (1995).
3. A. Lampen, U. Christians, F. P. Guengerich, P. B. Watkins, J. C. Kolars, A. Bader, A. K. Gonschior, H. Dralle, I. Hackbarth, and K. F. Sewing. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab. Dispos. 23:1315-1324 (1995).
4. L. M. Mancinelli, L. Frassetto, L. C. Floren, D. Dressler, S. Carrier, I. Bekersky, L. Z. Benet, and U. Christians. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. 69:24-31 (2001).
5. P. E. Wallemacqand, and R. K. Verbeeck. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin. Pharmacokinet. 40:283-295 (2001).
6. R. Venkataramanan, A. Swaminathan, T. Prasad, A. Jain, S. Zuckerman, V. Warty, J. McMichael, J. Lever, G. Burckart, and T. Starzl. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29:404-430 (1995).
7. P. A. Jacobson, C. E. Johnson, N. J. West, and J. A. Foster. Stability of tacrolimus in an extemporaneously compounded oral liquid. Am. J. Health-Syst. Pharm. 54:178-180 (1997).
8. K. Yamashita, T. Nakate, K. Okimoto, A. Ohike, Y. Tokunaga, R. Ibuki, K. Higaki, and T. Kimura. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 267:79-91 (2003).
9. H. Arima, K. Yunomae, F. Hirayama, and K. Uekama. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther. 297:547-555 (2001).
10. H. Arima, K. Yunomae, K. Miyake, T. Irie, F. Hirayama, and K. Uekama. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J. Pharm. Sci. 90:690-701 (2001).
11. M. J. Lee, R. M. Straubinger, and W. J. Jusko. Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (Fk-506) in rats. Pharm. Res. 12:1055-1059 (1995).
12. S. D. Moffatt, V. McAlister, R. Y. Calne, and S. M. Metcalfe. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. Transplantation 67:1205-1208 (1999).
13. O. Canadas, R. Guerrero, R. Garcia-Canero, G. Orellana, M. Menendez, and C. Casals. Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity. Biochemistry 43:9926-9938 (2004).
14. H. Egawa, S. Maeda, E. Yonemochi, T. Oguchi, K. Yamamoto, and Y. Nakai. Solubility parameter and dissolution behavior of cefalexin powders with different crystallinity. Chem. Pharm. Bull. 40:819-820 (1992).
15. T. Sato, A. Okada, K. Sekiguchi, and Y. Tsuda. Difference in physico-pharmaceutical properties between crystalline and noncrystalline 9,3′-diacetylmidecamycin. Chem. Pharm. Bull. 29:2675-2682 (1981).
16. H. Imaizumi, N. Nambu, and T. Nagai. Pharmaceutical interaction in dosage forms and processing.18. stability and several physical-properties of amorphous and crystalline forms of indomethacin. Chem. Pharm. Bull. 28:2565-2569 (1980).
17. P. Gao, M. E. Guyton, T. H. Huang, J. M. Bauer, K. J. Stefanski, and Q. Lu. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev. Ind. Pharm. 30:221-229 (2004).
18. S. L. Raghavan, B. Kiepfer, A. F. Davis, S. G. Kazarian, and J. Hadgraft. Membrane transport of hydrocortisone acetate from supersaturated solutions; the role of polymers. Int. J. Pharm. 221:95-105 (2001).
19. S. L. Raghavan, A. Trividic, A. F. Davis, and J. Hadgraft. Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int. J. Pharm. 193:231-237 (2000).
20. J. H. Hu, K. P. Johnston, and R. O. Williams. Stable amorphous danazol nanostructured powders with rapid dissolution rates produced by spray freezing into liquid. Drug Dev. Ind. Pharm. 30:695-704 (2004).
21. J. M. Vaughn, J. T. McConville, M. T. Crisp, R. O. Williams III, and K. P. Johnston. Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution (EPAS) and spray freezing into liquid(SFL) technologies. Drug Dev. Ind. Pharm. 32:559-567 (2006).
22. K. A. Overhoff, K. P. Johnston, and R. O. Williams. Improvement of dissolution rate of poorly water soluble drugs using a new particle engineering process: Spray freezing into liquid. In S. Svenson (ed), Polymeric Drug Delivery II: Polymeric Matrices and Drug Particle Engineering, American Chemical Society, Washington, DC, 2006, pp. 305-319.
23. K. A. Overhoff, J. Engstrom, B. Chen, B. Scherzer, T. E. Milner, K. P. Johnston, and R. O. Williams. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water soluble drugs. Eur. J. Pharm. Biopharm. 65:57-67 (2006).
24. T. L. Rogers, J. H. Hu, Z. S. Yu, K. P. Johnston, and R. O. Williams III. A novel particle engineering technology: spray-freezing into liquid. Int. J. Pharm. 242:93-100 (2002).
25. J. M. Vaughn, J. T. McConville, D. Burgess, R. L. Talbert, J. I. Peters, R. O. Williams III, and K. P. Johnston. Single dose and multiple dose studies of aerosolized itraconazole nanoparticles. Eur. J. Pharm. Biopharm. 63:95-102 (2005).
26. N. A. Megrab, A. C. Williams, and B. W. Barry. Estradiol permeation through human skin and silastic membrane-effects of propylene-glycol and supersaturation. J. Control. Release 36:277-294 (1995).
27. M. H. Sung, J. S. Kim, W. S. Kim, and I. Hirasawa. Modification of crystal growth mechanism of yttrium oxalate in metastable solution. J. Cryst. Growth. 235:529-540 (2002).
28. S. L. Lawand, and J. B. Kayes. Adsorption of non-ionic water-soluble cellulose polymers at the solid water interface and their effect on suspension stability. Int. J. Pharm. 15:251-260 (1983).
29. S. L. vanRagha, A. Trividic, A. F. Davis, and J. Hadgraft. Crystallization of hydrocortisone acetate: influence of polymers. Int. J. Pharm. 212:213-221 (2001).
30. F. Usui, K. Maeda, A. Kusai, K. Nishimura, and K. Yamamoto. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. Int. J. Pharm. 154:59-66 (1997).
31. H. Suzukiand, and H. Sunada. Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers. Chem. Pharm. Bull. 46:482-487 (1998).
32. A. J. Mackellar, G. Buckton, J. M. Newton, and C. A. Orr. The controlled crystallization of a model powder. 2. Investigation into the mechanism of action of poloxamers in changing crystal properties. Int. J. Pharm. 112:79-85 (1994).
33. K. Ueda, K. Shimojo, T. Shimazaki, I. Kado, and K. Honbo. Solid Dispersion of FR-900506 substance. United States Patent US4,916,138. (1990).
34. T. Nishikawa, H. Hasumi, S. Suzuki, H. Kubo, and H. Ohtani. Kinetic-analysis of molecular interconversion of immunosuppressant Fk506 by high-performance liquid-chromatography. Pharm. Res. 10:1785-1789 (1993).
35. S. Brunauer, P. H. Emmett, and E. Teller. Adsorption of gases in multimolecular layers. J. Am. Chem. Soc. 60:309-319 (1938).
36. J. Dietemann, P. Berthoux, J. P. Gay-Montchamp, M. Batie, and F. Berthoux. Comparison of ELISA method versus MEIA method for daily practice in the therapeutic monitoring of tacrolimus. Nephrol. Dial. Transplant 16:2246-2249 (2001).
37. S. Chutimaworapan, G. C. Ritthidej, E. Yonemochi, T. Oguchi, and K. Yamamoto. Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Dev. Ind. Pharm. 26:1141-1150 (2000).
38. J. T. McConville, K. A. Overhoff, P. Sinswat, J. M. Vaughn, B. L. Frei, D. S. Burgess, R. L. Talbert, J. I. Peters, K. P. Johnston, and R. O. Williams. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res. 23:901-911 (2006).
39. S. Tamura, A. Ohike, R. Ibuki, G. L. Amidon, and S. Yamashita. Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J. Pharm. Sci. 91:719-729 (2002).
40. E. Dutkiewiczand, and A. Jakubowska. Effect of electrolytes on the physicochemical behaviour of sodium dodecyl sulphate micelles. Colloid Polym. Sci. 280:1009-1014 (2002).
41. V. V. Khutoryanskiy, G. A. Mun, Z. S. Nurkeeva, and A. V. Dubolazov. pH and salt effects on interpolymer complexation via hydrogen bonding in aqueous solutions. Polym. Int. 53:1382-1387 (2004).
42. N. Pandit, T. Trygstad, S. Croy, M. Bohorquez, and C. Koch. Effect of salts on the micellization, clouding, and solubilization behavior of pluronic F127 solutions. J. Colloid Interface. Sci. 222:213-220 (2000).
43. L. Z. Benet, T. Izumi, Y. C. Zhang, J. A. Silverman, and V. J. Wacher. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control. Release 62:25-31 (1999).
44. Y. Hashimoto, H. Sasa, M. Shimomura, and K. Inui. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm. Res. 15:1609-1613 (1998).
45. K. Yokogawa, M. Takahashi, I. Tamai, H. Konishi, M. Nomura, S. Moritani, K. Miyamoto, and A. Tsuji. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm. Res. 16:1213-1218 (1999).
46. W. L. Chiou, S. M. Chung, and T. C. Wu. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm. Res. 17:205-208 (2000).
47. H. Saitoh, Y. Saikachi, M. Kobayashi, M. Yamaguchi, M. Oda, Y. Yuhki, K. Achiwa, K. Tadano, Y. Takahashi, and B. J. Aungst. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Eur. J. Pharm. Sci. 28:34-42 (2006).
48. A. Kagayama, S. Tanimoto, J. Fujisaki, A. Kaibara, K. Ohara, K. Iwasaki, Y. Hirano, and T. Hata. Oral absorption of Fk506 in rats. Pharm. Res. 10:1446-1450 (1993).
49. J. H. Lin. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23:1008-1021 (1995).